Investment case
Disc Medicine, Inc.
DISC · 2 developments mapped · last assessed 2026-09-01
Market Ontology has mapped 2 macro, policy, and market developments to Disc Medicine, Inc. since 2026-09-01. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for DISC yet, so no modelled value is shown. The DISC valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run DISC on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Open question
Disc Medicine to Present Phase 2 Hematology Data at SOHO 2026
Direct clinical trial data release for lead assets, impacting future revenue potential and perceived risk.
· Moves probability of success for disc 3405 and disc 0974, peak sales estimates for disc 3405 and disc 0974, discount rate reflecting clinical risk
What changed, by assumption
- 2026-09-01Disc Medicine to Present Phase 2 Hematology Data at SOHO 2026
- 2026-09-01Disc Medicine to Present Phase 2 RESTORE-PV and RALLY-MF Trial Data at SOHO
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-01 | Disc Medicine to Present Phase 2 Hematology Data at SOHO 2026 | mixed | 1-3m | 0.90 |
| 2026-09-01 | Disc Medicine to Present Phase 2 RESTORE-PV and RALLY-MF Trial Data at SOHO | mixed | 1-3m | 0.90 |